GR1001124B
(el)
*
|
1989-11-20 |
1993-04-28 |
Pfizer |
Θεραπευτικοι παραγοντες κουινουκλιδινης.
|
UA41251C2
(uk)
*
|
1990-01-04 |
2001-09-17 |
Пфайзер, Інк. |
Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
|
US5332817A
(en)
*
|
1990-01-04 |
1994-07-26 |
Pfizer Inc. |
3-aminopiperidine derivatives and related nitrogen containing heterocycles
|
US5232929A
(en)
*
|
1990-11-28 |
1993-08-03 |
Pfizer Inc. |
3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
|
US5364943A
(en)
*
|
1991-11-27 |
1994-11-15 |
Pfizer Inc. |
Preparation of substituted piperidines
|
ATE113947T1
(de)
*
|
1990-06-01 |
1994-11-15 |
Pfizer |
3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
|
EP0540526B1
(de)
*
|
1990-07-23 |
1994-12-28 |
Pfizer Inc. |
Chinuclidinderivate
|
EP0550635B1
(de)
*
|
1990-09-28 |
1995-04-19 |
Pfizer Inc. |
Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen
|
US5138060A
(en)
*
|
1991-01-03 |
1992-08-11 |
Pfizer Inc. |
Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
|
US5216163A
(en)
*
|
1991-01-03 |
1993-06-01 |
Pfizer Inc |
Process for preparing azabicyclo[2.2.2]octan-3-imines
|
HUT65612A
(en)
*
|
1991-01-10 |
1994-07-28 |
Pfizer |
Process n-alcyl-quinuclidinium salts of p-antagonistic activity
|
DE69220258T2
(de)
*
|
1991-02-11 |
1997-12-18 |
Merck Sharp & Dohme |
Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung
|
ES2065175T3
(es)
*
|
1991-03-01 |
1995-02-01 |
Pfizer |
Derivados de 1-azabiciclo(3.2.2)nonan-3-amina.
|
BR9205807A
(pt)
*
|
1991-03-26 |
1994-06-28 |
Pfizer |
Preparação estéreo-seletiva de piperidinas substituidas
|
FR2676442B1
(fr)
*
|
1991-05-17 |
1993-08-06 |
Rhone Poulenc Rorer Sa |
Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
|
US5716965A
(en)
*
|
1991-05-22 |
1998-02-10 |
Pfizer Inc. |
Substituted 3-aminoquinuclidines
|
WO1992020661A1
(en)
*
|
1991-05-22 |
1992-11-26 |
Merck & Co., Inc. |
N, n-diacylpiperazines
|
HUT65771A
(en)
*
|
1991-05-22 |
1994-07-28 |
Pfizer |
Process for producing substituted 3-amino-quinuclidine derivatives and pharmaceutical compositions containing them
|
UA27776C2
(uk)
*
|
1991-05-31 |
2000-10-16 |
Пфайзер Інк. |
Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
|
KR0154882B1
(ko)
*
|
1991-06-20 |
1998-11-16 |
알렌 제이. 스피겔 |
질소 함유 헤테로사이클릭 화합물의 플루오로알콕시벤질아미노 유도체
|
TW202432B
(de)
*
|
1991-06-21 |
1993-03-21 |
Pfizer |
|
US5288730A
(en)
*
|
1991-06-24 |
1994-02-22 |
Merck Sharp & Dohme Limited |
Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
|
EP0536817A1
(de)
*
|
1991-07-05 |
1993-04-14 |
MERCK SHARP & DOHME LTD. |
Azabicyclische Verbindungen als Tachykinin-Antagonisten
|
MY110227A
(en)
*
|
1991-08-12 |
1998-03-31 |
Ciba Geigy Ag |
1-acylpiperindine compounds.
|
EP0600952B1
(de)
*
|
1991-08-20 |
1996-04-17 |
MERCK SHARP & DOHME LTD. |
Azacyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
|
EP1082959A1
(de)
*
|
1991-09-20 |
2001-03-14 |
Glaxo Group Limited |
NK1 Antagonisten zur Behandlung von Depression
|
US5527808A
(en)
*
|
1991-09-26 |
1996-06-18 |
Pfizer Inc. |
Fused tricyclic nitrogen containing heterocycles
|
WO1993009116A1
(en)
*
|
1991-11-07 |
1993-05-13 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Quinuclidine compound and medicinal use thereof
|
DK0613458T3
(da)
*
|
1991-11-12 |
1998-02-09 |
Pfizer |
Acykliske ethylendiaminderivater som substans P receptorantagonister
|
FR2688219B1
(fr)
|
1992-03-03 |
1994-07-08 |
Sanofi Elf |
Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
|
JP2656702B2
(ja)
*
|
1992-03-23 |
1997-09-24 |
ファイザー製薬株式会社 |
ペプチド性キヌクリジン
|
WO1993021181A1
(en)
*
|
1992-04-15 |
1993-10-28 |
Merck Sharp & Dohme Limited |
Azacyclic compounds
|
US5444074A
(en)
*
|
1992-04-15 |
1995-08-22 |
Merck Sharp & Dohme Limited |
Piperidine tachykinin receptor antagonists
|
CA2134964C
(en)
*
|
1992-05-18 |
1997-12-30 |
Manoj C. Desai |
Bridged aza-bicyclic derivatives as substance p antagonists
|
US5637699A
(en)
*
|
1992-06-29 |
1997-06-10 |
Merck & Co., Inc. |
Process for preparing morpholine tachykinin receptor antagonists
|
US5719147A
(en)
*
|
1992-06-29 |
1998-02-17 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
US6048859A
(en)
|
1992-06-29 |
2000-04-11 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
JP2683783B2
(ja)
*
|
1992-07-10 |
1997-12-03 |
雪印乳業株式会社 |
シェーグレン症候群治療剤
|
GB9216911D0
(en)
*
|
1992-08-10 |
1992-09-23 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5721255A
(en)
*
|
1992-08-19 |
1998-02-24 |
Pfizer Inc. |
Substituted benzylamino nitrogen containing non-aromatic heterocycles
|
US5387595A
(en)
*
|
1992-08-26 |
1995-02-07 |
Merck & Co., Inc. |
Alicyclic compounds as tachykinin receptor antagonists
|
FR2695641B1
(fr)
*
|
1992-09-11 |
1994-11-25 |
Rhone Poulenc Rorer Sa |
(Amino-3 phényl)-1 éthanesulfonate d'hydroquinine optiquement actif, sa préparation et son utilisation.
|
JP2656699B2
(ja)
*
|
1992-10-21 |
1997-09-24 |
ファイザー製薬株式会社 |
置換ベンジルアミノキヌクリジン
|
US5604241A
(en)
*
|
1992-10-21 |
1997-02-18 |
Pfizer Inc. |
Substituted benzylaminoquinuclidines as substance P antagonists
|
US5837711A
(en)
*
|
1992-10-28 |
1998-11-17 |
Pfizer Inc. |
Substituted quinuclidines as substance P antagonists
|
JP2656700B2
(ja)
*
|
1992-10-28 |
1997-09-24 |
ファイザー製薬株式会社 |
置換キヌクリジン誘導体
|
ES2096312T3
(es)
*
|
1992-11-12 |
1997-03-01 |
Pfizer |
Derivado de quinuclidina como antagonista de la sustancia p.
|
US5344830A
(en)
*
|
1992-12-10 |
1994-09-06 |
Merck & Co., Inc. |
N,N-diacylpiperazine tachykinin antagonists
|
WO1994013663A1
(en)
*
|
1992-12-10 |
1994-06-23 |
Pfizer Inc. |
Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists
|
US5830854A
(en)
*
|
1992-12-14 |
1998-11-03 |
Merck Sharp & Dohme, Limited |
Method of treating cystic fibrosis using a tachykinin receptor antagonist
|
ATE166650T1
(de)
*
|
1993-03-04 |
1998-06-15 |
Pfizer |
Spiroazacyclischderivate als substanz p antagonisten
|
US5496833A
(en)
*
|
1993-04-13 |
1996-03-05 |
Merck Sharp & Dohme Limited |
Piperidine tachykinin receptor antagonists
|
IL109646A0
(en)
*
|
1993-05-19 |
1994-08-26 |
Pfizer |
Heteroatom substituted alkyl benzylamino-quinuclidines
|
JP2822274B2
(ja)
*
|
1993-05-19 |
1998-11-11 |
ファイザー製薬株式会社 |
P物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
|
US5393762A
(en)
*
|
1993-06-04 |
1995-02-28 |
Pfizer Inc. |
Pharmaceutical agents for treatment of emesis
|
US5348955A
(en)
*
|
1993-06-22 |
1994-09-20 |
Merck & Co., Inc. |
N,N-diacylpiperazines
|
ES2121213T3
(es)
*
|
1993-07-15 |
1998-11-16 |
Pfizer |
Benciloxiquinuclidinas como antagonistas de la sustancia p.
|
US5854262A
(en)
*
|
1993-10-07 |
1998-12-29 |
Pfizer Inc. |
Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
|
US5922878A
(en)
*
|
1994-03-03 |
1999-07-13 |
Boehringer Ingelheim Gmbh |
Amino acid derivatives, processes for preparing them and pharmaceutical compositions containing these compounds
|
PE45195A1
(es)
*
|
1994-03-03 |
1996-01-17 |
Boehringer Ingelheim Kg |
Derivado de aminoacido, procedimiento para su preparacion y composicion farmaceutica que lo contiene
|
IL112778A0
(en)
*
|
1994-03-04 |
1995-05-26 |
Merck & Co Inc |
Substituted heterocycles, their preparation and pharmaceutical compositions containing them
|
US6203803B1
(en)
|
1994-12-14 |
2001-03-20 |
Societe L'oreal S.A. |
Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
|
FR2719474B1
(fr)
*
|
1994-05-05 |
1996-05-31 |
Oreal |
Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
|
FR2719476B1
(fr)
*
|
1994-05-05 |
1997-05-23 |
Oreal |
Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
|
TW397825B
(en)
*
|
1994-10-14 |
2000-07-11 |
Novartis Ag |
Aroyl-piperidine derivatives
|
FR2725900B1
(fr)
*
|
1994-10-21 |
1997-07-18 |
Sanofi Sa |
Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
|
IL116249A
(en)
*
|
1994-12-12 |
2003-07-06 |
Pfizer |
Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
|
FR2728169A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
|
FR2728166A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Composition topique contenant un antagoniste de substance p
|
FR2728165A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
|
FR2729954B1
(fr)
|
1995-01-30 |
1997-08-01 |
Sanofi Sa |
Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
|
JP3042894B2
(ja)
|
1995-07-07 |
2000-05-22 |
ファイザー製薬株式会社 |
サブスタンスpアンタゴニストとしての置換ベンゾラクタム化合物
|
US6288225B1
(en)
|
1996-05-09 |
2001-09-11 |
Pfizer Inc |
Substituted benzolactam compounds as substance P antagonists
|
PE8798A1
(es)
*
|
1995-07-17 |
1998-03-02 |
Pfizer |
Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
|
TW458774B
(en)
|
1995-10-20 |
2001-10-11 |
Pfizer |
Antiemetic pharmaceutical compositions
|
FR2741262B1
(fr)
|
1995-11-20 |
1999-03-05 |
Oreal |
Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
|
MX9706944A
(es)
*
|
1996-09-12 |
1998-08-30 |
Pfizer |
Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
|
US6117855A
(en)
|
1996-10-07 |
2000-09-12 |
Merck Sharp & Dohme Ltd. |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
|
US6613765B1
(en)
|
1996-12-02 |
2003-09-02 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
US6114315A
(en)
*
|
1996-12-02 |
2000-09-05 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
|
US6100256A
(en)
*
|
1996-12-02 |
2000-08-08 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptors antagonists for treating schizophrenic disorders
|
US5977104A
(en)
*
|
1996-12-02 |
1999-11-02 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating bipolar disorders
|
JP2001504851A
(ja)
*
|
1996-12-02 |
2001-04-10 |
メルク シヤープ エンド ドーム リミテツド |
性的機能不全の治療のためのnk−1受容体拮抗薬の使用
|
CA2273853A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating cognitive disorders
|
CA2273856A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating bipolar disorders
|
JP2001507678A
(ja)
*
|
1996-12-02 |
2001-06-12 |
メルク シヤープ エンド ドーム リミテツド |
運動障害の治療のためのnk−1受容体拮抗薬の使用
|
JP2001504853A
(ja)
*
|
1996-12-02 |
2001-04-10 |
メルク シヤープ エンド ドーム リミテツド |
物質使用障害の治療のためのnk−1受容体拮抗薬の使用
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
US6087348A
(en)
*
|
1997-12-01 |
2000-07-11 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating stress disorders
|
US6271230B1
(en)
|
1997-12-01 |
2001-08-07 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating cognitive disorders
|
US6156749A
(en)
*
|
1997-12-01 |
2000-12-05 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating movement disorders
|
ATE238044T1
(de)
*
|
1998-08-25 |
2003-05-15 |
Novartis Pharma Gmbh |
Verwendung von substanz p antagonisten zur behandlung des chronischen ermüdungssyndroms und/oder der fibromyalgie
|
US6387925B1
(en)
*
|
1999-06-01 |
2002-05-14 |
Pfizer Inc. |
Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
|
US6262067B1
(en)
*
|
1999-06-22 |
2001-07-17 |
Pfizer Inc. |
Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
|
CA2324116A1
(en)
*
|
1999-10-25 |
2001-04-25 |
Susan Beth Sobolov-Jaynes |
Nk-1 receptor antagonists and eletriptan for the treatment of migraine
|
RU2309953C2
(ru)
|
1999-11-03 |
2007-11-10 |
Эймр Текнолоджи, Инк. |
Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
|
US7163949B1
(en)
|
1999-11-03 |
2007-01-16 |
Amr Technology, Inc. |
4-phenyl substituted tetrahydroisoquinolines and use thereof
|
USRE44578E1
(en)
|
2000-04-10 |
2013-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
|
IL142810A0
(en)
*
|
2000-05-03 |
2002-03-10 |
Pfizer Prod Inc |
Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
|
KR100821410B1
(ko)
|
2000-07-11 |
2008-04-10 |
에이엠알 테크놀로지, 인크. |
4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
|
US20020049211A1
(en)
*
|
2000-09-06 |
2002-04-25 |
Sobolov-Jaynes Susan Beth |
Combination treatment for depression and anxiety
|
EP1192952A3
(de)
*
|
2000-09-28 |
2003-03-26 |
Pfizer Products Inc. |
Ein NK-3 rezeptorantagonisten und ein ZNS-penetrierende NK-1 rezeptorantagonisten enthaltende Zusammensetzung zur Behandlung von Depression und Angst
|
PL367944A1
(en)
*
|
2001-07-20 |
2005-03-07 |
Pfizer Products Inc. |
Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
|
US6861526B2
(en)
*
|
2002-10-16 |
2005-03-01 |
Pfizer Inc. |
Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
|
WO2004067703A2
(en)
*
|
2003-01-31 |
2004-08-12 |
Pfizer Products Inc. |
5ht7 antagonists and inverse agonists
|
US20050136487A1
(en)
*
|
2003-10-27 |
2005-06-23 |
Meyer Donald W. |
Transmissible spongiform encephalopathy detection in cervids, sheep and goats
|
WO2005051919A1
(en)
*
|
2003-11-26 |
2005-06-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
ZA200701232B
(en)
|
2004-07-15 |
2008-08-27 |
Amr Technology Inc |
Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
EP1904069B1
(de)
|
2005-07-15 |
2018-06-13 |
Albany Molecular Research, Inc. |
Aryl- und heteroarylsubstituierte tetrahydrobenzazepine und verwendung damit zur wiederaufnahmeblockierung von norepinephrin, dopamin und serotonin
|
US8293900B2
(en)
|
2005-09-29 |
2012-10-23 |
Merck Sharp & Dohme Corp |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
BRPI0806245B1
(pt)
|
2007-01-10 |
2022-01-25 |
Msd Italia S.R.L. |
Compostos de fórmula i e seus usos
|
KR20090112722A
(ko)
|
2007-01-24 |
2009-10-28 |
글락소 그룹 리미티드 |
3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 r(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 nk1을 포함하는 제약 조성물
|
CA2682727C
(en)
|
2007-04-02 |
2016-03-22 |
Banyu Pharmaceutical Co., Ltd. |
Indoledione derivative
|
EP2170076B1
(de)
|
2007-06-27 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino-derivate als histondeacetylase-hemmer
|
US8598184B2
(en)
|
2008-03-03 |
2013-12-03 |
Tiger Pharmatech |
Protein kinase inhibitors
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
AR071997A1
(es)
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
UA105182C2
(ru)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
|
MX2011004551A
(es)
|
2008-10-30 |
2011-05-25 |
Merck Sharp & Dohme |
Antagonistas del receptor de orexina de isonicotinamida.
|
TW201031664A
(en)
*
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
KR20120034644A
(ko)
|
2009-05-12 |
2012-04-12 |
알바니 몰레큘라 리써치, 인크. |
아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
|
CN102638982B
(zh)
|
2009-05-12 |
2015-07-08 |
百时美施贵宝公司 |
(S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
|
CA2760837C
(en)
|
2009-05-12 |
2018-04-03 |
Albany Molecular Research, Inc. |
7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
|
WO2011046771A1
(en)
|
2009-10-14 |
2011-04-21 |
Schering Corporation |
SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
WO2012024170A2
(en)
|
2010-08-17 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
EP2615916B1
(de)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Kondensierte pyrazolderivate als neue erk-hemmer
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
JP2014514321A
(ja)
|
2011-04-21 |
2014-06-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
インスリン様増殖因子1受容体阻害剤
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
US10154988B2
(en)
|
2012-11-14 |
2018-12-18 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
MX363243B
(es)
|
2012-11-28 |
2019-03-14 |
Merck Sharp & Dohme |
Composiciones para tratar cáncer y usos de dichas composiciones.
|
RU2690663C2
(ru)
|
2012-12-20 |
2019-06-05 |
Мерк Шарп И Доум Корп. |
Замещенные имидазопиридины в качестве ингибиторов hdm2
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
NL2015865B1
(en)
|
2015-11-27 |
2017-06-13 |
Le Vet B V |
Maropitant Formulation.
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3833668A4
(de)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
Prmt5-inhibitoren
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
EP4010314B1
(de)
|
2019-08-08 |
2024-02-28 |
Merck Sharp & Dohme LLC |
Heteroaryl-pyrrolidin- und piperidinorexinrezeptor-agonisten
|
AU2021329805B2
(en)
|
2020-08-18 |
2024-02-29 |
Merck Sharp & Dohme Llc |
Bicycloheptane pyrrolidine orexin receptor agonists
|